Reversal of cisplatin resistance in vivo by an anti-fos ribozyme

Tadao Funato, Tomonori Ishii, Mariko Kanbe, Kevin J. Scanlon, Takeshi Sasaki

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Human colon cancer cells, SW480DDP and SW620DDP, which express fos gene highly, are resistant to cisplatin treatment. We prepared a hammerhead ribozyme to selectively cleave fos mRNA and revealed that the fos ribozyme significantly suppressed the expression of fos gene in resistant cells in vitro. The fos ribozyme which was transfected into the implanted tumor cells resistant to cisplatin, had also the ability to reduce the expression of fos gene in vivo, and reversed cell sensitivity to cisplatin. These results reinforce the potential role of anti-oncogene ribozymes in dealing with the problem of drug resistance, with new possible implications for gene targetting therapy.

Original languageEnglish
Pages (from-to)217-220
Number of pages4
JournalIn Vivo
Issue number3
Publication statusPublished - 1997
Externally publishedYes


  • C-fos
  • Cisplatin
  • Colon cancer
  • Drug-resistance
  • Ribozyme

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology


Dive into the research topics of 'Reversal of cisplatin resistance in vivo by an anti-fos ribozyme'. Together they form a unique fingerprint.

Cite this